Delamanid for extensively drug-resistant tuberculosis

New England Journal of Medicine

Volumn 373, Issue 3, 2015, Pages 291-292

  Gupta, Rajesh ^a   Geiter, Lawrence J ^a   Wells, Charles D ^a  

^a Otsuka Pharmaceutical Development and Commercialization   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAMANID; PLACEBO; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

BACTERIUM EXAMINATION; CAUSE OF DEATH; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FOLLOW UP; HUMAN; LETTER; MICROBIOLOGICAL PARAMETERS; NONHUMAN; OPEN STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM CULTURE; SPUTUM CULTURE CONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; CONTROLLED STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZED CONTROLLED TRIAL; SPUTUM;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; SPUTUM; TREATMENT OUTCOME;

EID: 84937026953     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1415332     Document Type: Letter

References (5)

1. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366:2151-60.
2. Wells C, Gupta R, Hittel N., et al. Long-term mortality assessment of multidrug resistant tuberculosis patients treated with delamanid. Eur Respir J 2015; 45:1-3.
3. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. Geneva: World Health Organization, 2008.
4. Notice to readers: revised definition of extensively drug-resistant tuberculosis. JAMA 2006; 296:2792.
5. Guidance for industry - pulmonary tuberculosis: developing drugs for treatment. Rockville, MD: Food and Drug Administration, November 2013.